Rattus norvegicus
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA92251 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Early full-term pregnancy affords lifetime protection against development of breast cancer. Parity-induced protection can be reproduced in a carcinogen-induced rat mammary carcinoma model. The molecular mechanisms of parity-induced protection against carcinogenic stimuli in rat mammary glands have not been fully characterized. In order to gain a better understanding of these molecular mechanisms, we performed gene expression analyses in parous and age-matched virgin (AMV) mammary glands of Lewis rats before and after carcinogen (N-methyl-N-nitrosourea; MNU) treatment. Keywords: other
2005-07-31 | GSE2726 | GEO
Project description:Early full-term pregnancy affords lifetime protection against development of breast cancer. Parity-induced protection can be reproduced in a carcinogen-induced rat mammary carcinoma model. The molecular mechanisms of parity-induced protection against carcinogenic stimuli in rat mammary glands have not been fully characterized. In order to gain a better understanding of these molecular mechanisms, we performed gene expression analyses in parous and age-matched virgin (AMV) mammary glands of Lewis rats before and after carcinogen (N-methyl-N-nitrosourea; MNU) treatment.
2008-06-12 | E-GEOD-2726 | biostudies-arrayexpress
Project description:Rat mammary cancer (spontaneous, radiation, MNU, PhIP, radiation + MNU, radiation + PhIP) (high corn oil diet)
| PRJNA191783 | ENA
Project description:Mammary gland gene expression timecourse with or without NMU treatment between Cop and F344 rat
| PRJNA107715 | ENA
Project description:Mammary gland development: cross-species analysis of the mammary gland transcriptome in pregnant or lactating wild type female Sprague Dawley rats.
| PRJNA128171 | ENA
Project description:Dietary soy effects on early rat mammary gland development
| PRJNA113735 | ENA
Project description:Male Sprague-Dawley rats were used to establish exhausted-exercise model by motorized rodent treadmill. Yu-Ping-Feng-San at doses of 2.18 g/kg was administrated by gavage before exercise training for 10 consecutive days. Quantitative proteomics was performed for assessing the related mechanism of Yu-Ping-Feng-San.
2022-08-12 | PXD032737 | Pride
Project description:Association of Cellular and Molecular Responses in the Rat Mammary Gland to 17beta-Estradiol with Susceptibility to Mammary Cancer
| PRJNA214313 | ENA
Project description:Early gene expression in salivary gland after isoproterenol treatment
| PRJNA238174 | ENA
Project description:Clinical studies have linked use of progestins (synthetic progesterone (P4)) to breast cancer risk. However, little is understood regarding the role native P4, signaling through the progesterone receptor (PR), plays in formation of breast tumors. Studies published by our lab highlighted a link between PR and immune signaling pathways, suggesting PR induces PR to repress the interferon signaling pathway. Given these findings, we sought to investigate whether P4/PR drive immunomodulation in the mammary gland and development of mammary gland tumors. We found that mice treated with P4 displayed changes in the mammary gland suggesting inhibited immune response compared to placebo-treated mice. Furthermore, transgenic mice with PR overexpression demonstrated decreased numbers of immune cell populations in their mammary gland, lymph nodes, and spleens. Upon long-term monitoring, we determined that multi-parous PR overexpressing mice developed significantly more mammary gland tumors than control mice. Additionally, tumors of PR overexpressing mice contained fewer infiltrating immune cells. Finally, RNA sequencing analysis of tumor samples revealed that immune-related gene signatures were enriched in tumors of control mice compared to tumors of PR overexpressing mice. Together, these findings provide a novel mechanism behind P4-mediated promotion of mammary gland tumor development and provide rationale to investigate anti-progestin treatment to promote immune-mediated elimination of mammary gland tumors.
2021-09-15 | GSE158134 | GEO